Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer — NEOMETRE  

Carcinoma Clinical Trial

Official title: Metformin in Association to Chemoradiotherapy for the Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Randomized, Placebo-controlled Phase II Study

Status Terminated

Clinical Trial Summary

A phase II, randomized study of placebo versus metformin in association to chemotherapy with capecitabine and radiation in the neoadjuvant treatment of locally advanced (T3-4N0M0 or TxN1-2M0) rectal carcinomas.

Clinical Trial Description

NEOMETRE is a randomized, double blind trial aiming to evaluate the efficacy and tolerability of metformin in association to chemoradiotherapy for the preoperative treatment of locally advanced (T3-4N0M0 or TxN1-2M0) rectal carcinomas.

Patients eligible for this study will be submitted to neoadjuvant 3D radiotherapy with 50,4 Gray (Gy) divided in 25 applications, in association to capecitabine, 825mg/m2 bid for five days every week. The participants will be randomized to daily metformin or placebo during the chemoradiotherapy period. The primary end-point is pathological complete response. The secondary end-points are recurrence-free survival (RFS), disease-free survival (DFS), overall survival (OS), local recurrence rate, overall response rate, sphincter preservation rate, quality of life (QoL) and toxicity. ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma
• Rectal Neoplasms

• NCT number: NCT02473094
• Study type: Interventional
• Source: University of Campinas, Brazil
• Status: Terminated
• Phase: Phase 2
• Start date: July 2015
• Completion date: February 2016